{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:11Z","timestamp":1792740731235,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.07.016","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T15:31:44Z","timestamp":1532705504000},"page":"5309-5317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents \u2013 Results from a randomized, controlled, observer-blind phase II study"],"prefix":"10.1016","volume":"36","author":[{"given":"Jo Anne","family":"Welsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Senders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Essink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pedotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Barbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.07.016_b0005","first-page":"E116","article-title":"Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage","volume":"56","author":"Gabutti","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2018.07.016_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2018.07.016_b0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.07.016_b0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2018.07.016_b0025","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2018.07.016_b0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","article-title":"Meningococcal serogroup B vaccines: estimating breadth of coverage","volume":"13","author":"Donald","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.07.016_b0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba): a review in active immunization against invasive meningococcal group B disease in individuals aged 10\u201325 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2018.07.016_b0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero: prospects for reducing the burden of meningococcal serogroup B disease","volume":"34","author":"Watson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-013-0155-7","article-title":"A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program","volume":"74","author":"O'Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.07.016_b0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.07.016_b0055","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.07.016_b0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.07.016_b0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.07.016_b0070","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.07.016_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.016_b0080","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.07.016_b0085","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0090","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0095","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2015.11.070","article-title":"High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland","volume":"34","author":"Wasko","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, NHBA (gna2132), NadA, PorA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.07.016_b0110","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.vaccine.2015.02.049","article-title":"Antibody persistence 5 years after vaccination at 2 to 10 years of age with quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0115","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal Antigen Typing System (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States","volume":"2","author":"Rajam","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2018.07.016_b0120","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0125","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.07.016_b0130","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.016_b0135","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1080\/21645515.2015.1029686","article-title":"Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents","volume":"11","author":"Saez-Llorens","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.07.016_b0140","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1097\/INF.0000000000000822","article-title":"Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents","volume":"34","author":"Saez-Llorens","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.07.016_b0145","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.07.016_b0150","doi-asserted-by":"crossref","first-page":"520","DOI":"10.15585\/mmwr.mm6520a3","article-title":"Notes from the field: Outbreak of serogroup B meningococcal disease at a university - California, 2016","volume":"65","author":"Biswas","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.07.016_b0155","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.07.016_b0160","first-page":"606","article-title":"Serogroup B meningococcal disease outbreak and carriage evaluation at a college - Rhode Island, 2015","volume":"64","author":"Soeters","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.07.016_b0165","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.07.016_b0170","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.07.016_b0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2016.11.014","article-title":"Complement: a primer for the coming therapeutic revolution","volume":"172","author":"Barnum","year":"2017","journal-title":"Pharmacol Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T21:58:39Z","timestamp":1604699919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":35,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18309460"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents \u2013 Results from a randomized, controlled, observer-blind phase II study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}